DEPO - Depomed, Inc.

NasdaqGS - NasdaqGS Delayed Price. Currency in USD
7.30
+0.12 (+1.67%)
As of 4:00PM EDT. Market open.
Stock chart is not supported by your current browser
Previous close7.18
Open7.16
Bid0.00 x 2900
Ask0.00 x 1300
Day's range7.09 - 7.42
52-week range4.31 - 9.48
Volume940,193
Avg. volume1,405,195
Market cap464.188M
Beta1.04
PE ratio (TTM)N/A
EPS (TTM)-0.67
Earnings date5 Nov 2018 - 9 Nov 2018
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target est9.00
Trade prices are not sourced from all markets
  • GlobeNewswirelast month

    Depomed Inc. Announces Corporate Name Change to Assertio Therapeutics, Inc.

    Assertio Therapeutics, Inc. (NASDAQ:ASRT), a leading specialty pharmaceutical company committed to advancing patient care, has announced that its corporate name change from “Depomed, Inc.” to “Assertio Therapeutics, Inc.” became effective at 11:59 p.m. ET yesterday, August 14, 2018. In connection with the name change, the Company’s common stock will begin trading under a new ticker symbol “ASRT” and a new CUSIP number, 04545L 107, at the opening of trading today, August 15, 2018. “Over the last several years, we have taken strategic actions to transition the Company to focus on our neurology, orphan and specialty medicines,” said Arthur Higgins, President and CEO of Assertio Therapeutics, Inc. “As we’ve transformed, it has become clear that the name Depomed no longer accurately reflects the business we’re in today or the future direction in which we’re headed.

  • Associated Presslast month

    Depomed: 2Q Earnings Snapshot

    The Newark, California-based company said it had a loss of 33 cents per share. Earnings, adjusted for non-recurring costs and stock option expense, were 19 cents per share. The results exceeded Wall Street ...

  • GlobeNewswirelast month

    Depomed Announces Second-Quarter 2018 Financial Results

    --Raises Full-Year Earnings and Adjusted EBITDA Guidance Range and Lowers Full-Year Net Sales Guidance Range for the Neurology Franchise--. --Confirms Regulatory Plan to File for FDA Approval of Cosyntropin ...

  • GlobeNewswire2 months ago

    Factors of Influence in 2018, Key Indicators and Opportunity within Finisar, Albireo Pharma, Corporate Office Properties Trust, Ocean Power Technologies, Depomed, and Potbelly — New Research Emphasizes Economic Growth

    NEW YORK, July 31, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Finisar ...

  • GlobeNewswire2 months ago

    Report: Developing Opportunities within Facebook, Depomed, Freeport-McMoRan, The Home Depot, Earthstone Energy, and Nuance Communications — Future Expectations, Projections Moving into 2018

    NEW YORK, July 30, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Facebook, ...

  • The Wall Street Journal2 months ago

    [$$] Depomed, Purdue Pharma Move to Resolve Patent Dispute

    Inc. and Purdue Pharma LP are trying to resolve a patent dispute involving Purdue’s painkiller OxyContin. The companies didn’t disclose terms of the settlement talks Monday, but Janney Montgomery Scott’s Ken Trbovich said a settlement could “easily support the lower end” of his April 2016 forecast of potential royalties for Depomed of $3 to $8 a share on an estimated $10 billion in cumulative OxyContin sales. By Mr. Trbovich’s estimate, Depomed could bring in about $190 million, or about one-third of its market value as of Monday’s closing, which reflected a 19% surge on news of the settlement discussions.

  • GlobeNewswire2 months ago

    Depomed to Report Second-Quarter 2018 Financial Results on Wednesday, August 8, 2018

    LAKE FOREST, Ill., July 09, 2018-- Depomed, Inc. today announced that it will release second-quarter 2018 financial results on Wednesday, August 8, 2018, before the open of markets. Following the announcement, ...

  • GlobeNewswire2 months ago

    Depomed Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

    Depomed, Inc. (DEPO) announced that effective July 3, 2018, the Company granted ten newly-hired employees a total of 512,439 restricted stock units (“RSUs”).  The RSUs were granted as inducements material to each such individual’s entry into employment with Depomed in accordance with NASDAQ Listing Rule 5635(c)(4).  The RSUs are subject to such employee’s continued service relationship with the Company, the terms and conditions of the Company's 2014 Omnibus Incentive Plan and the award agreements pursuant to which they were granted. Depomed is a leading specialty pharmaceutical company committed to putting the patient first in everything it does. Depomed is focused on enhancing the lives of patients, families, physicians, providers and payors through the commercialization of products in the areas of pain and neurology, and in the development of drugs in areas of unmet medical need.

  • Why Depomed Inc.'s Shares Soared 23.2% Higher
    Motley Fool4 months ago

    Why Depomed Inc.'s Shares Soared 23.2% Higher

    The company rewarded investors with good news today.

  • Associated Press4 months ago

    Depomed: 1Q Earnings Snapshot

    The Newark, California-based company said it had net income of 48 cents per share. Earnings, adjusted for non-recurring gains, were 28 cents per share. The results topped Wall Street expectations. The ...

  • Drug stocks dive as Trump says he's considering suing drugmakers over opioid crisis
    CNBC6 months ago

    Drug stocks dive as Trump says he's considering suing drugmakers over opioid crisis

    President Donald Trump said he's considering suing drugmakers for their role in fueling the opioid epidemic, sending pharma stocks tumbling.

  • This Biotech Flirts With Breakout Amid Battle With Opioid Makers
    Investor's Business Daily6 months ago

    This Biotech Flirts With Breakout Amid Battle With Opioid Makers

    Collegium touched a buy zone Thursday after sales of painkiller Xtampza easily beat Street expectations in the fourth quarter.

  • Exploring Depomed’s Financial Performance Today
    Market Realist6 months ago

    Exploring Depomed’s Financial Performance Today

    In fiscal 2017, Depomed (DEPO) generated total revenues of $380.7 million. Of these total revenues, $379.8 million came from product sales, and ~$844,000 came from royalties. By comparison, the company had generated total revenues of $455.8 million in fiscal 2016, of which $455 million came from product sales and $831 million from royalties.

  • Depomed versus Peers in March 2018: Analyst Ratings
    Market Realist6 months ago

    Depomed versus Peers in March 2018: Analyst Ratings

    Depomed (DEPO) is a specialty pharmaceutical company with a focus on pain and CNS (central nervous system) conditions. In March 2018, two of the seven analysts covering Depomed have given the stock a “buy” rating. By comparison, of the 22 analysts covering Merck (MRK) in March 2018, six analysts have given the stock a “strong buy” rating, and seven analysts have given it a “buy” rating, while nine analysts have given it a “hold” rating.